Raptiva falloff weighs on Merck KGaA

Hit by a decline in demand for the psoriasis drug Raptiva--recently linked to the deaths of two patients who developed the rare brain infection PML (progressive multifocal leukoencephalopathy)--Merck KGaA posted a fourth-quarter loss of 279.5 million euros ($374 million). Report